Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FoxM1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
FoxM1 siRNA is a research-stage small interfering RNA (siRNA) designed to target and silence the FOXM1 (Forkhead Box M1) gene. FOXM1 is an oncogenic transcription factor that is frequently overexpressed in various human cancers, where it regulates the expression of genes involved in cell cycle progression (G1/S and G2/M transitions), cell proliferation, and tumorigenesis. By degrading FOXM1 mRNA, the siRNA prevents the translation of the FOXM1 protein, leading to reduced levels of downstream targets such as cdc25B, Aurora B Kinase, and Skp2. In preclinical models, including breast and ovarian cancer xenografts, FoxM1 siRNA has demonstrated the ability to inhibit tumor growth, induce apoptosis, and reduce cell migration and invasion. It is primarily utilized as a research tool and experimental therapeutic candidate.
- Other names
- anti-FoxM1 siRNAanti-FoxM-1 siRNAanti-FoxM 1 siRNAFOXM1 siRNAFOXM-1 siRNAFOXM 1 siRNA
02
Targets
Innate immune RNA sensorsFOXM1 (Forkhead box protein M1)
Beyond the preview
Go deeper on FoxM1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FoxM1 siRNA.